Antiverse, an AI-driven techbio company developing therapeutic antibodies for historically undruggable targets, has raised a $9.3 million Series A and announced a research agreement with the Cystic Fibrosis Foundation.

The round was led by Soulmates Ventures with participation from Innovation Investment Capital, DOMiNO Ventures, and existing investors, bringing total funding to over $20 million. Proceeds will advance Antiverse’s internal pipeline toward in vivo efficacy studies and further scale its generative AI platform and in-house lab capabilities.

Under the new agreement, Antiverse will design and optimize novel antibodies targeting the extracellular region of CFTR — a notoriously difficult domain — using its AI-driven modelling platform and proprietary lab-in-the-loop workflow, before transferring candidates to the Foundation for testing in native cell models.